Document Detail

Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses.
MedLine Citation:
PMID:  12589349     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Montelukast, a leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction. We and others have shown that there is a late-phase response 3 to 8 hours after exercise in a subset of asthmatic patients. OBJECTIVE: We sought to evaluate the protective effect of montelukast on immediate-phase and late-phase responses after exercise challenges. METHODS: Twenty-two atopic asthmatic children aged 7 to 16 years with reproducible exercise-induced bronchoconstriction (minimum of 15% decrease of FEV(1) from baseline) were enrolled in this placebo-controlled crossover study. Exercise challenges were performed while breathing cold dry air, and FEV(1) measurements were taken up to 480 minutes after exercise. Patients underwent exercise challenges on a screening day and 1 week after placebo treatment. Subsequently, after a week with no treatment, pulmonary function was assessed after breathing dry cold air (control day). Finally, an exercise challenge was carried out after a week of treatment with montelukast. RESULTS: Reproducible late-phase reactions occurred in 5 of 22 patients, which correlated with the extent of the immediate response (P <.05). After 1 week of treatment with montelukast, a significant decrease of immediate responses was observed. Montelukast treatment compared with placebo was associated with a lower mean maximum decrease of FEV(1) (mean +/- SEM: 17.3% +/- 2.4% and 35.1% +/- 2.6%, respectively), decrease of the area above the curve (267.8% +/- 42.7%/min and 868.0% +/- 103.8%/min, respectively), and shorter time for recovery (6.9 +/- 1.1 minutes and 30.9 +/- 4.0 minutes, respectively; P <.05). Treatment with montelukast also abolished late-phase responses. CONCLUSION: Once daily treatment with oral montelukast attenuated the immediate-phase response and abolished the late-phase response induced by means of exercise challenge in asthmatic children.
Raul E Melo; Dirceu Solé; Charles K Naspitz
Related Documents :
12589349 - Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-...
21247919 - Prognostic significance of different measures of the ventilation-carbon dioxide relatio...
12065349 - Exhaled nitric oxide and bronchial responsiveness to adenosine 5'-monophosphate in subj...
2032979 - Retention and clearance of 0.9-micron particles inhaled by hamsters during rest or exer...
2828449 - Mechanisms of acute increases in airway responsiveness caused by environmental chemicals.
2679269 - Use and misuse of metered-dose inhalers by patients with chronic lung disease. a contro...
7149099 - An onchocercal nodule appearing during diethylcarbamazine therapy.
9153969 - Exercise performance after ptmc in mitral stenosis: the relation with hemodynamics, ven...
7225749 - The relationship between the number of capillaries in the skin of the venous ulcer-bear...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of allergy and clinical immunology     Volume:  111     ISSN:  0091-6749     ISO Abbreviation:  J. Allergy Clin. Immunol.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-17     Completed Date:  2003-03-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1275002     Medline TA:  J Allergy Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  301-7     Citation Subset:  AIM; IM    
Division of Allergy, Clinical Immunology, and Rheumatology, Department of Pediatrics, Federal University of São Paulo-Escola Paulista de Medicina, Rua dos Otonis 725, 04025-002 São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetates / administration & dosage,  therapeutic use*
Administration, Oral
Anti-Asthmatic Agents / administration & dosage,  therapeutic use*
Asthma / drug therapy*,  physiopathology*
Bronchoconstriction / drug effects*
Cross-Over Studies
Forced Expiratory Volume
Leukotriene Antagonists / administration & dosage,  therapeutic use
Quinolines / administration & dosage,  therapeutic use*
Reg. No./Substance:
0/Acetates; 0/Anti-Asthmatic Agents; 0/Leukotriene Antagonists; 0/Quinolines; 158966-92-8/montelukast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure ...
Next Document:  Circadian variation of sputum inflammatory cells in mild asthma.